Results of Nucleos(t)ide Analog Treatment Discontinuation in Hepatitis B e-Antigen-Negative Chronic Hepatitis B: NUCSTOP Study
Open Access
- 2 January 2024
- journal article
- research article
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 35 (1) , 17-26
Abstract
Background/Aims: This study aims to investigate the effects of nucleos(t)ide analogs (NAs) discontinuation in eligible patients in accor dance with the Asian Pacific Association for the Study of the Liver hepatitis B guideline and the factors affecting clinical and virological relapses. Materials and Methods: In this prospectively designed study, hepatitis B e antigen (HBeAg)-negative chronic hepatitis B patients who were followed up between 2012 and 2019 were evaluated and 57 patients were included. All participants enrolled the study were HBeAg negative status at NA initiation. Results: The median age of the patients was 49 (29-72) years and 24 (42%) were females. The median treatment duration was 96 (36 276) months and patients were followed for a median duration of 27 months. Sixteen patients had a previous history of NA switch, and thirteen of these patients had a history of lamivudine resistance. Thirty-eight of 57 patients (66%) developed an elevated hepatitis B virus deoxyribonucleic acid level of >2000 IU/mL at least once, defined as virological relapse and 23 (60%) of them, experienced clinical relapse. Thirty-one of 57 patients were re-treated during the follow-up, and hepatitis B surface antigen (HBsAg) loss occurred among 4 (7%) patients. All patients who experienced HBsAg loss had a history of lamivudine resistance (P = .002). Conclusion: Despite receiving NAs suppression therapy for a long time, HBsAg loss occurs rarely. Although it was not life-threatening, most patients experienced relapses and treatment should be restarted. In our study, whether it is a coincidence that all patients with HBsAg loss are patients in whom NAs are used sequentially due to lamivudine resistance is an issue that needs to be further investigated. Cite this article as: Kiremitçi S, Koçhan K, Seven G, et al. Results of nucleos(t)ide analog treatment discontinuation in hepatitis B e-antigen-negative chronic hepatitis B: NUCSTOP study. Turk J Gastroenterol. 2024;35(1):17-26.Keywords
This publication has 29 references indexed in Scilit:
- Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in CaucasiansGut, 2014
- Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective studyGut, 2014
- Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNAScience, 2014
- Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patientsHepatology, 2013
- Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide AnaloguesGastroenterology, 2012
- Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With AdefovirGastroenterology, 2012
- Prevalence of and Risk Factors for Hepatitis B Viremia After Spontaneous Hepatitis B Surface Antigen Seroclearance in Hepatitis B CarriersClinical Infectious Diseases, 2011
- Incidence and Determinants of Spontaneous Hepatitis B Surface Antigen Seroclearance: A Community-Based Follow-Up StudyGastroenterology, 2010
- Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppressionJournal of Clinical Virology, 2009